16.30
Schlusskurs vom Vortag:
$16.10
Offen:
$16.19
24-Stunden-Volumen:
912.25K
Relative Volume:
0.75
Marktkapitalisierung:
$1.82B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-11.64
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
-2.92%
1M Leistung:
-2.34%
6M Leistung:
-39.24%
1J Leistung:
-13.67%
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Vergleichen Sie NVCR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NVCR
Novocure Ltd
|
16.30 | 1.87B | 577.74M | -149.78M | -78.21M | -1.40 |
![]()
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-08-04 | Eingeleitet | SVB Securities | Outperform |
2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
2022-02-08 | Eingeleitet | Loop Capital | Buy |
2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
2022-01-20 | Hochstufung | Truist | Hold → Buy |
2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
2021-01-25 | Bestätigt | Piper Sandler | Overweight |
2020-09-23 | Eingeleitet | Northland Capital | Outperform |
2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-09-17 | Herabstufung | Truist | Buy → Hold |
2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
2019-03-20 | Eingeleitet | SunTrust | Hold |
2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
2018-04-18 | Bestätigt | Mizuho | Buy |
2018-02-23 | Bestätigt | Mizuho | Buy |
2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
2016-07-29 | Bestätigt | Wedbush | Outperform |
2016-01-19 | Eingeleitet | Barclays | Underweight |
2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
What drives NovoCure Limited stock priceRobust investment performance - jammulinksnews.com
Is NovoCure Limited a good long term investmentUnmatched market gains - jammulinksnews.com
M&T Bank Corp Sells 1,750 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Limited Stock Analysis and ForecastExplosive portfolio gains - jammulinksnews.com
How NovoCure Limited stock performs during market volatilityBreakout Level Watch - Newser
What makes NovoCure Limited stock price move sharplyFree Stock Market Group - Newser
Why NovoCure Limited stock attracts strong analyst attentionFast Growing Stocks - Newser
NovoCure (NASDAQ:NVCR) shareholders are up 4.2% this past week, but still in the red over the last three years - simplywall.st
Teacher Retirement System of Texas Buys 3,123 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
Most Volatile Stocks in the US (July 2025) - Investing.com
NovoCure Ltd Stock Price Falls 3.41% Amid Analyst Predictions of 81.88% Upside - AInvest
LADENBURG THALM/SH SH Initiates Coverage on NovoCure (NASDAQ:NVCR) - Defense World
NovoCure stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com South Africa
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
NovoCure stock initiated with Buy rating at Ladenburg Thalmann - Investing.com
NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data - Investing.com Nigeria
New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan
Novocure to Present Final Secondary Endpoint Data from the Phase - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Novocure to Report Second Quarter 2025 Financial Results | NVCR Stock News - GuruFocus
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Demystifying NovoCure: Insights From 4 Analyst Reviews - Nasdaq
NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable - simplywall.st
Rhumbline Advisers Has $2.69 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles By Investing.com - Investing.com South Africa
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles - Investing.com India
NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView
Mackenzie Financial Corp Purchases Shares of 6,820 NovoCure Limited (NASDAQ:NVCR) - Defense World
Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus
Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment - Investing.com
Ameriprise Financial Inc. Has $682,000 Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data - Investing.com Nigeria
NovoCure Ltd (NVCR) Shares Down 7.43% on Jun 2 - GuruFocus
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Yahoo Finance
Novocure (NVCR) Gains Support for Future Launch from Promising T - GuruFocus
Novocure (NVCR) Gains Support for Future Launch from Promising Trial Outcomes | NVCR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data By Investing.com - Investing.com South Africa
NovoCure Announces Positive Phase 3 Trial Results - TipRanks
Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News - GuruFocus
Novocure announces results from Phase 3 PANOVA-3 trial - TipRanks
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 - GuruFocus
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Lelezard
Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | NVCR Stock News - GuruFocus
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Yahoo Finance
NovoCure Ltd (NVCR) Shares Gap Down to $18.5801 on May 30 - GuruFocus
Nuveen Asset Management LLC Lowers Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):